ALXP
ALNFL
Market cap5mUSD
Oct 28, Last price
0.42EUR
1D
-5.78%
1Q
-49.94%
IPO
-87.95%
Name
Nfl Biosciences SAS
Chart & performance
P/E
—
P/S
—
EPS
—
Vol. 1Y
55.12%
Shs. 5Y
—
Rev. 5Y
%
Div Yld LY
—
Div Yld TTM
—
Revenues
0
Net income
-3m
CFO
0
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Established in 2006 and headquartered in Castelnau-le-Lez, France, NFL Biosciences S.A. is a biotechnology enterprise dedicated to pioneering natural remedies for addiction cessation, particularly for individuals seeking to quit smoking. Their most advanced therapeutic candidate, NFL-101, derived from tobacco, is currently progressing through Phase III clinical trials specifically designed to combat smoking addiction. Additionally, the company's research pipeline features NFL-201, an extract blending cannabis and tobacco, and NFL-301, a botanical formulation rooted in traditional Chinese medicine, both of which are undergoing preclinical assessment.
Headquarters & legal address
199 RUE HELENE BOUCHER
CASTELNAU-LE-LEZ 34170
FR
CASTELNAU-LE-LEZ 34170
FR
Trading name
SMOKE FREE THERAPEUTICS
Valuation
Title EUR in thousands, except ratios and share amounts | FY |
|---|---|
| 2025‑12 | |
| Income | |
Revenues | |
Cost of revenue | |
Unusual Expense (Income) | |
NOPBT | |
NOPBT Margin | |
Operating Taxes | |
Tax Rate | |
NOPAT | |
Net income | |
Dividends | |
Dividend yield | |
Proceeds from repurchase of equity | |
BB yield | |
| Debt | |
Debt current | |
Long-term debt | |
Deferred revenue | |
Other long-term liabilities | |
Net debt | |
| Cash flow | |
Cash from operating activities | |
CAPEX | |
Cash from investing activities | |
Cash from financing activities | |
FCF | |
| Balance | |
Cash | |
Long term investments | |
Excess cash | |
Stockholders' equity | |
Invested Capital | |
ROIC | |
ROCE | |
| EV | |
Common stock shares outstanding | |
Price | |
Market cap | |
EV | |
EBITDA | |
EV/EBITDA | |
Interest | |
Interest/NOPBT | |